Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : TAK crawled time : 13:20 save search
Takeda Receives FDA Approval to Expand the Use of HYQVIA® to Treat Primary Immunodeficiency in Children
Published: 2023-04-11 (Crawled : 13:20) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.36%
H: 0.35%
C: -0.12%
hyqvia fda children approval
Takeda to Acquire Nimbus Therapeutics’ Highly Selective, Allosteric TYK2 Inhibitor to Address Multiple Immune-Mediated Diseases
Published: 2022-12-13 (Crawled : 13:20) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 2.21%
H: 0.66%
C: -0.07%
acquire
LIVTENCITY (maribavir) receives positive CADTH recommendation for adults with post-transplant cytomegalovirus (CMV) infection
Published: 2022-12-01 (Crawled : 13:20) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.75%
H: 0.57%
C: 0.2%
cytomegalovirus positive infection
Prometheus Laboratories Announces Partnership with Takeda to Launch CDPATH™, a Personalized Prognostic Tool Advancing Innovation for Crohn's Disease Patients
Published: 2022-09-14 (Crawled : 13:20) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.0%
H: 0.52%
C: 0.15%
partnership disease innovation
Immusoft Announces FDA Clearance of IND Application for ISP-001 for MPS I, the First Engineered B Cell Therapy to Enter into Clinical Trials
Published: 2022-09-01 (Crawled : 13:20) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.36%
H: 0.58%
C: 0.29%
isp-001 fda clearance trials application therapy mps-ih mps-i
Global Rheumatology Therapeutics Market Research Report to 2027 - Featuring AbbVie, Amgen and Beckman Coulter Among Others
Published: 2022-04-26 (Crawled : 13:20) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.81%
H: 0.0%
C: 0.0%
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 3.09%
H: 0.0%
C: -2.9%
UCBJY | $63.676 -4.38% 7.2K
|
Manufacturing
|
| O: -0.33%
H: 0.0%
C: -1.56%
TMO | News | $544.78 0.6% 0.0% 1.7M
|
Health Technology
|
| O: -1.19%
H: 0.0%
C: 0.0%
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.48%
H: 0.0%
C: 0.0%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 3.08%
H: 0.0%
C: 0.0%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 2.0%
H: 0.0%
C: 0.0%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.34%
H: 1.41%
C: -1.17%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.09%
H: 1.26%
C: -0.51%
VRTX | News | $394.43 0.24% 0.24% 1.3M
|
Health Technology
|
| O: -0.22%
H: 0.43%
C: -1.25%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.11%
H: 0.0%
C: 0.0%
RIGL | $1.07 1.91% 1.87% 810K
|
Health Technology
|
| O: -0.38%
H: 4.92%
C: -4.55%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: -0.72%
H: 0.0%
C: 0.0%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.13%
H: 0.0%
C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.03%
H: 0.53%
C: -1.33%
research report therapeutics market
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.